Glaukos (GKOS)
(Delayed Data from NYSE)
$99.48 USD
-0.63 (-0.63%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $99.49 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Glaukos (GKOS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$106.25 | $120.00 | $84.00 | 6.13% |
Price Target
Based on short-term price targets offered by 12 analysts, the average price target for Glaukos comes to $106.25. The forecasts range from a low of $84.00 to a high of $120.00. The average price target represents an increase of 6.13% from the last closing price of $100.11.
Analyst Price Targets (12)
Broker Rating
Glaukos currently has an average brokerage recommendation (ABR) of 1.64 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 14 brokerage firms. The current ABR compares to an ABR of 1.64 a month ago based on 14 recommendations.
Of the 14 recommendations deriving the current ABR, nine are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 64.29% and 7.14% of all recommendations. A month ago, Strong Buy made up 64.29%, while Buy represented 7.14%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 9 | 9 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 4 | 4 | 4 | 4 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.64 | 1.64 | 1.64 | 1.64 | 1.54 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/11/2024 | Mizuho SecuritiesUSA | Anthony Petrone | Hold | Hold |
3/22/2024 | Truist Securities | Samuel E Brodovsky | Strong Buy | Strong Buy |
2/27/2024 | BTIG | Ryan Zimmerman | Strong Buy | Strong Buy |
2/16/2024 | Needham & Company | David Saxon | Moderate Buy | Moderate Buy |
1/16/2024 | Stephens | George Sellers | Strong Buy | Strong Buy |
12/22/2023 | Piper Sandler | Matthew O'Brien | Strong Buy | Strong Buy |
11/2/2023 | William Blair | Margaret Kaczor | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.64 |
ABR (Last week) | 1.64 |
# of Recs in ABR | 14 |
Average Target Price | $106.25 |
LT Growth Rate | NA |
Industry | Medical - Instruments |
Industry Rank by ABR | 94 of 252 |
Current Quarter EPS Est: | -0.59 |